{"entity":{"id":"paper-tung-tbcrc048-expansion-jco-2026","kind":"paper","name":"TBCRC 048 expansion: olaparib in metastatic breast cancer with germline PALB2 or somatic BRCA","aka":[],"tldr":"Olaparib shrank some metastatic breast cancers with tumour-only BRCA mutations. This does not establish benefit in preventing recurrence after surgery.","summary":"Phase 2 expansion with 24 germline PALB2 and 30 somatic BRCA1/2 participants. The overall population comprised 42 ER-positive/HER2-negative, seven TNBC and five HER2-positive cancers. Participants received single-agent olaparib until progression. Somatic-BRCA activity was clinically meaningful but missed the prespecified response target.","asOf":"2026-10-10","links":[{"label":"Primary publication","url":"https://doi.org/10.1200/JCO-25-02075"},{"label":"PubMed record","url":"https://pubmed.ncbi.nlm.nih.gov/41604601/"}],"tags":[],"related":[],"cancers":["breast-cancer","tnbc"],"sections":[],"technologies":[],"targets":["parp"],"drugs":["olaparib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct03344965"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"journal":"Journal of Clinical Oncology","year":2026,"doi":"10.1200/JCO-25-02075","pmid":"41604601","authors":"Tung NM, Robson ME, Li T, et al.","paperType":"translational","findings":["Somatic BRCA1/2: 11/30 responses, ORR 36.7% (80% CI 24.7 to 50.0), median PFS 5.5 months (90% CI 2.8 to 8.3), median response duration 11.2 months (90% CI 4.4 to not reached).","Germline PALB2: ORR 75% (80% CI 60.2 to 86.3), median PFS 9.4 months (90% CI 8.3 to 13.1)."],"whatItMeans":"Metastatic single-arm evidence does not supply a somatic-only adjuvant indication or a personal response probability.","caveats":["Metastatic single-arm evidence does not supply a somatic-only adjuvant indication or a personal response probability.","Only seven participants overall had TNBC; somatic cohort mixed BRCA1 and BRCA2, 15 each."],"participants":54},"route":"/key-papers/paper-tung-tbcrc048-expansion-jco-2026/","neighbours":{"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"target":[{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/"}],"drug":[{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/"}],"trial":[{"id":"nct03344965","kind":"trial","name":"Olaparib In Metastatic Breast Cancer","route":"/trials/nct03344965/"}]}}